Pharma Stocks Soar: Ajanta, Zydus, Emcure Jump on Key Deals & Approvals

• Ajanta Pharma partnered with Biocon for exclusive marketing of Semaglutide in 23 countries, boosting its international portfolio.
• Zydus Lifesciences collaborated with Bioeq AG for US commercialization of NUFYMCO, an interchangeable biosimilar for eye diseases, following USFDA approval.
• Emcure Pharma received a 'No Action Indicated' (NAI) status from USFDA for its Gujarat unit, signaling no regulatory issues.
• Shares of Ajanta Pharma and Zydus Lifesciences saw significant gains, with Ajanta surging up to 4.5%.
• Emcure Pharma's shares, despite positive USFDA news, ended the day in the red after early gains.

Why It Matters: Key deals, approvals, and positive USFDA reports drove pharma stock movements, highlighting sector activity.